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Summary Monoclonal antibody (MAb) 139H2 was previously shown to localise specifically into ovarian
cancer xenografts in nude mice. MAb 139H2 was compared with MAbs OC125 and OV-TL 3, all reactive with
ovarian carcinomas, for the binding characteristics as IgG and F(ab')2 fragments with the use of the
OVCAR-3 cell line grown in vitro and as s.c. xenografts. Immunoperoxidase staining of OVCAR-3 tissue
sections with MAbs OC125 and 139H2 was heterogeneous, whereas MAb OV-TL 3 showed homogeneity. No
differences in binding were observed between IgG and F(ab')2. The avidity expressed as apparent affinity
constants of MAbs OC125, OV-TL 3 and 139H2 for OVAR-3 cells were 1 x 109M- 1 x 109M-1, and
I x 108 M-, while the number of antigenic determinants were 5 x 106, 1 x 106 and 7 x 106, respectively. In
OVCAR-3 bearing nude mice the blood half-lives of the MAbs as IgG and F(ab')2 were approximately 50 h
and 6 h, respectively. Maximum tumour uptake for the whole MAbs OC125, OV-TL 3, 139H2 and a control
MAb 2C7 was 8.5%, 17.7%, 11.1% and 2.5% of the injected dose g-', reached at 72 h after injection. For the
respective F(ab')2 fragments, the maximum values were 5.2%, 10.0%, 5.5% and 1.9% of the injected dose g 1,
reached between 6 h and 15 h. Tumour to non-tumour ratios were more favourable for the F(ab')2 fragments
as compared to those for MAbs as IgG. Biodistribution in mice bearing a control tumour confirmed the
specificity of tumour localisation of MAbs OC125, OV-TL 3 and 139H2. After injection of a tracer dose of
10 iCi of radiolabelled MAbs OC125, OV-TL 3 and 139H2 as IgG, tumours received 38 cGy, 86 cGy and
39 cGy, respectively. For the respective F(ab')2 fragments, these doses were 6 cGy, 22 cGy and 9 cGy. In our
OVCAR-3 model, a ranking in efficiency in tumour localisation would indicate MAb OV-TL 3 as most
favourable MAb, but cross-reactivity with subpopulations of human white blood cells might hamper its
clinical use. Dosimetric data indicate a 4-fold higher radiation absorbed dose to tumours for IgG compared
with F(ab')2 fragments.
Specific tumour localisation using monoclonal antibodies
(MAbs) to tumour-associated antigens has shown to be suc-
cessful in a variety of malignancies. Immunoscintigraphic
detection of ovarian cancer lesions in patients has been per-
formed mostly with radiolabelled MAbs HMFG1 and
HMFG2 (Taylor-Papadimitriou et al., 1981; Rainsbury et al.,
1983) and with MAb OC125 (Bast et al., 1981). Another
MAb, designated as OV-TL 3, has recently been shown to
have good diagnostic accuracy in ovarian cancer (Massuger
et al., 1990; Buist et al., 1992). At present, it is not known
which MAb is most useful for tumour localisation in ovarian
cancer patients. Recently, we have characterised MAb 139H2
for its reactivity pattern in various types of ovarian tumours
(Molthoff et al., 1991a). MAb 139H2 was found to react
better than either MAbs HMFG1 and HMFG2, which are
all MAbs directed against the same antigen, episialin. There-
fore, we further analysed the in vivo characteristics of MAb
139H2 after radiolabelling and demonstrated specific tumour
localisation (Molthoff et al., 1991b).
Several variables have been described which may be impor-
tant for successful tumour localisation. Among them are the
specificity, the affinity, the origin and the size of the MAb,
the localisation and the number of antigenic determinants on
the tumour cells, the possible heterogeneity in antigen expres-
sion and the release of the antigen into the circulation. For
different MAbs, most of these variables can be analysed in
the laboratory before selecting the optimal antibody for diag-
nostic use in patients. For that purpose, human tumour cell
lines and human tumour xenografts are accepted tools,
because of the presence of a series of characteristics relevant
for immunological studies.
In the present study, we compared the binding characteris-
tics of MAb 139H2 with those of MAbs OC125 and OV-
TL 3 in order to assess the potential clinical utility of MAb
139H2. For the 3 MAbs, specificity was determined in vitro
as well as in nude mice bearing s.c. human ovarian cancer
xenografts (OVCAR-3). Furthermore, we compared the
differences between whole IgG and F(ab')2 fragments of the 3
MAbs, particularly with respect to pharmacokinetics, biodis-
tribution and dosimetry in tumour-bearing mice.
Materials and methods
Monoclonal antibodies
Some characteristics of the MAbs OC125, OV-TL 3 and
139H2, all of the IgGI isotype, are presented in Table I.
MAb OC125 reacts with the cell-surface glycoprotein CA125
present on > 80% of the non-mucinous ovarian cancer sub-
types (Bast et al., 1981). MAb OV-TL 3 recognises a cell
surface antigenic determinant OA3, detectable on most ovar-
ian carcinomas (Poels et al., 1986). MAb 139H2 binds to a
protein determinant of episialin, also designated as MAM-6
or CA 15-3 (Hilkens et al., 1989). The majority of ovarian
carcinomas express episialin. The MAbs 2C7 and A2C6, used
as control antibodies, are also of the IgGI isotype. MAb 2C7
reacts with human a-glucocerebrosidase (Barneveld et al.,
1983) and MAb A2C6 reacts with the hepatitis B surface
antigen (Zurawski et al., 1983). Purified IgG of MAbs OC125
and OV-TL 3 was kindly provided by Dr S.O. Warnaar
(Centocor Inc., Leiden, The Netherlands). Purified MAb 2C7
was kindly provided by Dr J.M. Tager (University of Ams-
terdam, The Netherlands). Ascitic fluid containing MAb
139H2 was kindly provided by Dr J. Hilkens (Netherlands
Cancer Institute, Amsterdam). Purification of this antibody
was performed by affinity chromatography using Affi-Gel
Protein-A MAPS II (Bio-Rad Laboratories, Utrecht, The
Netherlands).
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Table I Characteristics of MAbs OC-125, OV-TL 3 and 139H2
Avidity Antigenic sites Antigen
MAb Specificity Isotype (M- ) on OVCAR-3 cells shedding
OC125 CA125 IgGI 109 5 x 106 yes
OV-TL 3 OA3 IgGI 109 1 x 106 no
139H2 episialin IgGI lo8 7 x 106 yes
F(ab')2fragments
Purified F(ab')2 fragments of MAbs OC125, OV-TL 3 and
A2C6 were also kindly provided by Dr Warnaar. F(ab')2
fragments of MAb 139H2 were prepared by pepsin digestion
of the 139H2 IgG. Immobilised pepsin (Pierce Europe BV,
Oud-Beijerland, The Netherlands) was rinsed with 0.1 M cit-
ric acid monohydrate/sodium hydroxide at buffer pH 3.5. Per
ml of purified IgG (1-5 mg ml-') in the same buffer, 30 lAl of
the washed immobilised pepsin was added and the incubation
lasted for 3th at 370C. The incubation was terminated by
addition of M Tris (hydroxy-methyl) aminomethane pH 9.0.
The immobilised pepsin was removed by centrifugation and
the fragments were purified by anion exchange FPLC using a
Mono QHR 5/5 column (Pharmacia LKB Biotechnology,
Woerden, The Netherlands). Purity of both whole IgG and
F(ab')2 fragments was demonstrated by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).
Cell lines
The NIH: OVCAR-3 (OVCAR-3) human ovarian cancer cell
line (Hamilton et al., 1983) was kindly donated by Dr T.C.
Hamilton (Fox Chase Cancer Center, Philadelphia, PA).
WiDr is a human colon cancer cell line described by Noguchi
et al. (1979). Colo 26 is a murine colon cancer cell line
established from murine Colo 26 tumours described by Cor-
bett et al. (1975). All cell lines were grown as a monolayer in
Dulbecco's modified Eagle's medium (DMEM) obtained
from Flow (Amsterdam, The Netherlands), supplemented
with heat-inactivated 10% fetal calf serum (FCS).
Tumour lines
OVCAR-3 and WiDr xenografts were established from cells
grown in vitro and injected s.c. in both flanks offemale, 8-10
week-old NMRI/Cpb (nu/nu) mice (Harlan/Cpb, Zeist, The
Netherlands). OVCAR-3 xenografts showed a poorly to
moderately differentiated serous adenocarcinoma pattern,
while that of WiDr was a poorly differentiated mucinous
adenocarcinoma. Murine Colo 26 tumours were established
in 7-8 week-old BALB/c mice (Harlan/Cpb, Zeist, The
Netherlands) and histology revealed an undifferentiated pat-
tern. The tumours were transferred by implanting fragments
of solid tissue with a diameter of 2-3 mm s.c. through a
small skin incision in subsequent recipients. Tumours were
measured in three dimensions and the volume was expressed
by the equation length x width x height x 0.5 in mm3. The
volume doubling times for OVCAR-3, WiDr and Colo 26
tumours were 10, 8 and 2+ days, respectively. Binding of
MAbs and F(ab')2 fragments to tumour cells was determined
in an indirect immunoperoxidase assay as has been described
earlier (Molthoff et al., 1991a).
Radiolabelling ofantibodies andfragments
Whole antibodies and fragments were labelled with either 1251I
or '3lI by the one-vial iodogen method (Haisma et al., 1986).
Free iodine was removed by an anion exchange resin suspen-
sion in PBS containing 1% BSA (AG1-X8, Bio-Rad, Utrecht,
The Netherlands). The percentage of radioactive iodine
bound to the MAb was determined by trichloroacetic acid
(TCA) precipitation and was always > 95%. The specific
activities of the iodinated MAbs ranged from 2 to 9 mCi/mg
(Table II).
Table II Specific activity and immunoreactivity of MAbs and
fragments
IgG F(ab')2
MAb SA* IRf SA IR
OC125 8.2 0.2 70.4±4.0 2.4± 1.0 83.8± 13.0
OV-TL 3 9.4 0.1 72.7 7.0 2.6 0.5 73.0 6.3
139H2 4.9 ± 1.8 67.0 ± 5.4 1.9 ± 0.8 64.5 ± 7.6
*SA = specific activity in mCi mg- ± s.d.; tIR = immunoreactivity
in % ± s.d.
Immunoreactivity andavidity
After radiolabelling, the immunoreactive fraction was deter-
mined on OVCAR-3, WiDr or Colo 26 cells according to
Lindmo et al. (1984). The immunoreactivities of the iodin-
ated MAbs were in the range of 65 to 84% (Table II). The
avidity of the specific MAbs was determined on OVCAR-3
cells by incubating a fixed amount of radiolabelled MAb
mixed with unlabelled MAb over a concentration range of
1-150fig ml-'. The cell-bound radioactivity was measured in
a gamma counter. The apparent affinity constant (avidity)
was calculated from a Scatchard plot of specifically bound
MAb versus bound over free MAb.
Pharmacokinetics and biodistribution
In mice, thyroid uptake of iodide was blocked by potassium
iodide to the drinking water (0.1%) from 3 days before until
the end of the study. Animals bearing OVCAR-3, WiDr or
Colo 26 tumours (120 ± 51 mm3) were injected with com-
binations of two radiolabelled MAbs (7-15 tCi per MAb),
since all MAbs were directed against different antigenic deter-
minants and the steric configuration did not hinder each
other's binding. Mice were sacrificed at 1, 3, 6, 15, 24, 48, 72
and 168 h after injection. For each time point three mice
were used. Blood was collected from mice under ether anaes-
thesia. Thereafter, normal tissues and tumours were dissec-
ted, rinsed in saline and dried to minimise blood residues.
Blood and all tissues were weighed and the radioactivity was
measured in a two-channel gamma counter with automatic
correction for spillover of both radionuclides in the channels.
To correct for radioactive decay, a standard solution of the
injected material was prepared and counted simultaneously
with the tissues at each day studied. The uptake of antibody
was expressed as the percentage of injected dose per gram.
The proportion of radioactivity associated with protein in
serum was determined by precipitation with 10% TCA.
Immune complex formation was analysed using gel filtration
Superose-6 or Superose-12 FPLC chromatography.
Radiation dose measurements and calculations
The approximate radiation doses to various tissues were
derived from the uptake data of the conjugate in each tissue
assuming uniform distribution of the radionuclide within the
organs. The absorbed dose was then calculated using the
trapezoid integration method for the area under the curve
(AUC) (Badger et al., 1985). These doses were expressed in
cGy by multiplying the integrated tLCi h g-' by the g.cGy
ytCi-'h-' factor for '"'I published by the Medical Internal
Radiation Dose committee (Dillman, 1969). The gamma-
radiation dose has been neglected because of low absorbed
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centration of the radiolabelled MAb in each organ was
assumed to be OsCig-1.
Results
In vitro characteristics ofMAbs
In an immunoperoxidase assay of cytospin preparations of
OVCAR-3 cells, MAbs OC125, OV-TL 3 and 139H2 (whole
antibody as well as fragments) were shown to strongly stain
these cells, whereas MAbs 2C7 and A2C6 were negative
(results not shown). None of the antibodies reacted with
WiDr and Colo 26 cells.
Immunoperoxidase staining of tissue sections of OVCAR-3
xenografts with MAbs OC125 and 139H2 was intense and
heterogeneously distributed. The binding of MAb 139H2 in
the more differentiated areas of the tumour was mainly
restricted to the apical cell membrane of the cells. Staining
with MAb OV-TL 3 showed a more homogeneous pattern in
OVCAR-3 tissue sections. No differences in staining were
observed between MAbs as IgG or as F(ab')2 fragments.
MAbs 2C7 and A2C6 did not react with OVCAR-3 tumour
tissue. WiDr tissue sections showed weak staining for MAb
OV-TL 3, and were negative for the other MAbs.
A Scatchard analysis was performed with the radiolabelled
MAbs on OVCAR-3 cells. The avidity, calculated as appar-
ent affinity constants, for MAbs OC125, OV-TL 3 and
139H2 were lx 109M-1, lx 109M-1 and lx 108M-1, res-
pectively (Table I). The number of antigenic sites per
OVCAR-3 cell for these MAbs was in the range of 1 x 106 to
7 x 106 per cell.
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Figure 1 Blood clearance of radiolabelled MAbs as IgG and
F(ab')2 fragments in nude mice bearing OVCAR-3 xenografts.
(0), '251-OC125; (U), '3I1-OVTL3; (A), "3'I-139H2; (*),
125I-2C7, s.d. < 16%.
Pharmacokinetics ofMAbs andfragments
OVCAR-3 bearing mice were injected with MAbs as IgG
with either the combination of '31I-MAb OV-TL 3 plus 125I-
MAb OC125 or with '31I-MAb 139H2 plus '25I-MAb 2C7.
Since F(ab')2 fragments of MAb 2C7 could not be made,
tumour-bearing mice were injected with MAbs as F(ab')2
fragments with the combination of '3'I-MAb OV-TL 3 plus
'25I-MAb OC125 or with '3iI-MAb A2C6 plus 251I-MAb
139H2. Figure 1 shows the pharmacokinetics of the radio-
labelled IgGs and F(ab')2 fragments in the blood. The
half-lives of MAbs OC125, OV-TL3 and 139H2 were ap-
proximately 50 h for IgG and 6 h for F(ab')2 fragments. A
similar clearance pattern was observed for the control MAbs.
The amount of free iodine in the serum, measured at each
time point was < 10%. Serum radioactivity profiles corres-
ponded to that of respectively IgG and F(ab')2 fragments and
no immune complexes were observed in the serum (not
shown).
Biodistribution ofMAbs andfragments
Figure 2 shows the uptake of the radiolabelled MAbs as IgG
and F(ab')2 over a time period of 7 days in the OVCAR-3
tumours. The maximum % of the injected doseg-' in
tumour tissue for MAbs OC125, OV-TL 3 and 139H2 as IgG
was 8.5%, 17.7% and 11.1%, respectively. This level was
reached 3 days after injection and the antibodies cleared
slowly from the tumour with half-lifes of >5 days. In con-
trast, the maximum % injected doseg-' for the control MAb
was 2.5% and no retention was observed. For the F(ab')2
fragments, the maximum % of the injected dose g-' in
tumour tissue for MAbs OC125, OV-TL 3 and 139H2 was
5.2%, 10.0% and 5.5%, respectively. This level was reached
6 to 15 h after injection. After that, no retention of the
fragnents in the tumour was observed. The respective F(ab')2
fragments cleared from the tumour with half-lives of 13 h,
33 h and 30 h, respectively. F(ab')2 fragments of MAb A2C6
reached a maximum of 1.9% of the injected doseg-' tumour
without retention. Results for IgG and fragments from the
biodistribution experiments in OVCAR-3 bearing mice are
summarised in Table III.
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Figure 2 Tumour uptake of radiolabelled MAbs as IgG and
F(ab')2 fragments in nude mice bearing OVCAR-3 xenografts.
(0), 125I-OC125; (U), 31I-OV TL 3; (A), 31I-139H2; (*),
125-I2C7, s.d. < 16%.
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For IgG as well as for F(ab')2 fragments of the three
MAbs OC125, OV-TL 3 and 139H2, uptake in normal or-
gans was much lower than in tumours. At 72 h after injec-
tion, liver uptake for the 3 IgGs was 1.5% of the injected
dose g-l. The amount of F(ab')2 fragments in the liver
measured 1.8% of the injected dose g' at 15 h after injec-
tion. Other tissues showed an equal or lower uptake com-
pared with that in the liver, except for the kidneys with
respect to the F(ab')2 fragments. Tumour to non-tumour
ratios varied largely between IgG and F(ab')2 fragments
(Table IV). For the F(ab')2 fragments of the three MAbs, the
tumour to blood ratios were approximately eight times as
high at 48 h as for IgG at 168 h. Also, tumour to normal
organ ratios were more favourable for F(ab')2 fragments as
compared to IgG.
For analysis of tumour specificity, biodistribution of MAbs
was examined in mice bearing WiDr colon cancer xenografts,
grown from a control cell line, which did not express the
relevant antigens. WiDr bearing mice were injected with
MAbs as IgG in a combination of '3II-MAb OV-TL 3 plus
251I-MAb OC125 IgG or with 131I-MAb 139H2. Serum half-
lives for MAbs OC125, OV-TL 3 and 139H2 were 44 h, 50 h
and 60 h, respectively (Figure 3). No major differences were
observed for the uptake in normal tissues between the three
MAbs. Tumour uptake of MAbs OC125 and 139H2 was low
and in the same order of magnitude as the negative control
MAb 2C7 in OVCAR-3 xenografts. Surprisingly, tumour
uptake of MAb OV-TL 3 was similar to that in the OVCAR-
3 xenografts. The maximum level was 18.3% of the injected
dose g-' in tumour tissue and was retained for > 5 days.
WiDr tissue sections were scored weakly positive for bin-
ding with MAb OV TL 3 in the immunoperoxidase assay
while the WiDr cell line was negative. As biodistribution of
MAb OV TL 3 in WiDr colon cancer xenografts was sugges-
tive for specific uptake, similar experiments were carried out
in the murine Colo 26 tumour model. After administration of
a tracer dose of '311-MAb OV-TL 3 plus 251I-MAb 139H2,
mice were sacrificed at 6h, 24h and 72h after injection.
Results are depicted in Figure 4. No specific tumour uptake
was observed and biodistribution in normal organs was
similar for both antibodies.
Dosimetry
Absorbed radiation doses to the blood, tumours and normal
tissues delivered by the radiolabelled MAbs were calculated
from the data of the biodistribution experiments. Results for
the various tumour lines and MAbs are summarised in Table
V. The absorbed radiation dose in OVCAR-3 xenografts
delivered by 10 ytCi radiolabelled MAbs OC125, OV-TL 3
and 139H2 as IgG was 38 cGy, 86 cGy and 39 cGy, respec-
tively. For the respective F(ab')2 fragments, the doses were
6 cGy, 22 cGy and 9 cGy. Doses to the blood exceeded those
to the tumours, with the exception of MAb OV-TL 3 for
both IgG as well as F(ab')2 fragments. Absorbed radiation
doses from radiolabelled MAbs OC125 and 139H2 to WiDr
colon cancer xenografts were nearly half of the doses de-
livered to OVCAR-3 tumours.
Discussion
The MAbs OC125, OV-TL 3 and 139H2 react with distinct
antigenic determinants associated with ovarian carcinomas.
MAbs OC125 and OV-TL 3 have been introduced in the
clinic for radioimmunoscintigraphy while MAb 139H2 is still
under preclinical investigation. We have shown that MAb
139H2 can specifically localise in human tumour xenografts.
In the present study, human cell lines grown in vitro and as
xenografts were used to compare the binding characteristics
of MAb 139H2 with those of MAbs OC125 and OV-TL 3.
Binding of the three MAbs was specific for tumours express-
ing the relevant antigen. Comparison of the MAbs as IgG
and F(ab')2 fragments in OVCAR-3 xenografts revealed a
4-6 fold lower absorbed radiation dose to tumours, but
considerably higher tumour to blood ratios for the F(ab')2
Table III Comparison of IgG and F(ab')2 fragments in OVCAR-3 bearing mice
IgG F(ab')2
Tumour* Blood Tumour Tumour Blood
MAb (4J (t) (t4)
OC125 8.5 1.9 (72) 52 5.2 ± 0.9 (15) 13 6
OV-TL 3 17.7 + 3.5 (72) 50 10.0 ± 1.5 (6-15) 33 7
139H2 11.1 1.9 (72) 48 5.5 ± 0.7 (15) 30 6
control 2.5 ± 0.8 50 1.9 ± 0.2 6
*Maximum percentage of injected dose gI ± s.d., between parentheses, time of
measurement (h). tHalf-life (h).
Table IV Tumour/non-tumour ratios after injection of a tracer dose of radiolabelled
MAbs
MAb Time* Blood Liver Spleen Intestine Muscle Femur
IgG
OC125 72 0.9 5.3 7.1 8.1 14.2 7.7
168 1.0 5.0 6.2 9.7 12.5 8.3
OV-TL 3 72 2.1 9.8 11.8 14.5 29.5 13.6
168 4.0 19.2 19.2 37.3 48.0 32.0
139H2 72 1.2 5.8 7.4 8.7 22.2 7.4
168 2.3 11.5 11.5 22.1 33.7 20.0
control 72 0.3 1.2 2.0 2.3 6.2 2.3
168 0.2 1.8 1.8 4.6 5.3 3.5
F(ab')2
OC125 24 2.1 5.0 6.8 11.6 26.6 12.0
48 8.0 11.3 16.1 10.7 26.5 7.5
OV-TL 3 24 4.9 17.0 14.8 19.2 58.1 24.9
48 37.8 98.2 98.2 76.4 163.7 164.0
139H2 24 2.2 6.4 6.9 11.1 27.1 13.1
48 20.2 42.6 46.3 67.2 54.0 90.0
control 24 0.2 0.8 0.6 2.7 7.1 3.3
48t
*h after injection; tnot determined.THREE MAbS AS IgG AND F(ab')2 IN OVARIAN CANCER 681
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Figure 4 Biodistribution of radiolabelled MAbN
and 139H2 (LII) injected into Balb/c mice
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after injection, s.d. < 12%.
fragments. Although a similar number of antigenic deter-
minants per cell was found in the human ovarian cancer cell
line OVCAR-3, uptake in OVCAR-3 xenografts was most
favourable for MAb OV-TL 3 as compared to that of MAbs
OC125 and 139H2. This finding could not be ascribed to a
difference in immunoglobulin isotype, to different affinities
for the target antigen or to immune complex formation.
The biodistribution studies in human tumour xenografts
indicated specific tumour localisation for all 3 MAbs. The
higher accumulation for MAb OV-TL 3 as compared to that
of MAb OC125 is in agreement with the results of Boerman
et al. (1990) with the use of the same OVCAR-3 model.
144 168 192 Mosely et al. (1988) observed a similar pattern with the
F{ah r r ^,4 'KA A Ike CfN'_ .,. r 'I ;-+- r au o 112iragmensL oi fVftUs tit-,1 .) dllU v - iL J1din 1 Ltra-
peritoneal tumour model. Although the WiDr cell line did
not express the OA3 antigen, uptake in WiDr xenografts of
radiolabelled MAb OV-TL 3 was as high as in the OVCAR-3
xenografts. A likely explanation may be the induction of the
OA3 antigen expression in WiDr cells grown as xenografts,
because no specific tumour localisation was observed in
murine Colo 26 tumours. Radiolabelled MAb 139H2 demon-
strated a maximum tumour uptake of 11.1% of the injected
dose g ', in OVCAR-3 bearing mice. In our OVCAR-3
model, a ranking efficiency in tumour localisation would
follow OV-TL3 > 139H2 >OC125.
Circulating antigen can cause immune comnlex formation
resulting in altered pharmacokinetics of the MAb and re-
duced uptake of antibody in tumours. Both MAbs OC125
of radiolabelled and 139H2 react with antigens which are shed from tumour
WiDr xenografts. cells. These circulating antigens, CA125 and episialin, are
9H2, s.d. < 19%. being used for the monitoring of ovarian cancer and breast
cancer patients, respectively (Kenemans et al., 1988). To
date, a variety of antibodies reactive with circulating anti-
gens, such as MAbs HMFG1, HMFG2, OC125 and also the
anti-carcinoembryonic antigen (CEA) MAbs, have been ap-
plied to many patients for successful detection of tumour
lesions. In OVCAR-3 bearing nude mice, low levels of
CA125 and episialin could be measured in the circulation
(Molthoff et al., 1991a). We were unable to demonstrate the
formation of immune complexes or accelerated clearance of
radiolahbllPd MAhb OC125 or 1 9H42 aAmini0tprpid to OV_ . .._,__vl-xt LP 1_1 71 _ aU111-O%w11U t %#
CAR-3 bearing nude mice. Therefore, circulating antigens
could not account for the differences in tumour uptake
between the three MAbs.
Antigen localisation and accessibility have been shown to
influence the tumour uptake of MAbs in vivo and can be
attributed to immunological and non-immunological factors
(reviewed by Jain et al., 1987). In this respect, important
immunological aspects are the number of antigenic deter-
minants per cell, the cellular site of antigen expression, and
the differentiation status of the cell and of the tumour.
Expression of episialin in normal glandular epithelia and
well-differentiated carcinomas is heterogeneous and detec-
table mostly at the apical cell membrane (Hilkens et al.,
s OV-TL 3 ( ) 1989). An increase in episialin determinants is often found in
bearing Colo 26 less differentiated carcinomas, where the glycoprotein is
gans, first 2 bars detected both intracellularly and on the entire cell surface. As
ars represent 48 h a consequence, episialin in normal epithelia and well-
differentiated tumours would be less accessible for MAb
Table V Dosimetry* of radiolabelled MAbs in tumour-bearing mice
OVCAR-3 WiDr
Tumour Blood Liver Tumour Blood Liver
OC125 IgG 38 64 12 24 75 16
OC125 F(ab')2 6 10 3
OV-TL3 IgG 86 51 14 75 55 16
OV-TL 3 F(ab')2 22 10 3
139H2 IgG 39 66 13 21 67 15
139H2 F(ab')2 9 8 2
control IgG 10 35 10
control F(ab')2 2 11 2
*Absorbed radiation doses in cGy 10peCi-' injected dose calculated over 0-168 h.
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139H2. The CA125 antigen is also expressed heterogeneously,
but on the entire cell membrane and no correlation has been
observed with the differentiation status of the tumour (Zur-
awski et al., 1988). The OA3 antigen is known to be
homogeneously distributed in tumour tissue and detectable
on the cell membrane as well as in the cytoplasm (Poels et
al., 1986). In the OVCAR-3 model, the homogeneous OA3
distribution could be an explanation for the increased tu-
mour uptake of MAb OV-TL 3.
Upon comparison of the binding characteristics of the
three MAbs, MAb OV-TL 3 would be most favourable for
clinical application. However, human tumour models may
not always predict the behaviour of a MAb administered to
patients. MAb OV-TL 3 was found to react with certain
subpopulations of human leucocytes and their progenitors
(unpublished data). Cross-reactivity with circulating cells in
patients has been described by Dillman et al. (1984) for an
anti-CEA MAb, which was associated with serious toxicity.
In the immunoscintigraphic study using radiolabelled MAb
OV-TL 3 in ovarian cancer patients (Buist et al., 1992), the
binding to white blood cells did not seem to interfere with
the imaging results or to cause side effects. Nevertheless,
significant binding to non-target cells may pose a major
limitation with respect to repeated administration or higher
doses of MAbs into patients.
High tumour to normal tissue ratios are considered to be
of advantage for the application of radiolabelled MAbs for
the detection of tumour lesions in cancer patients. In our
study, we observed higher tumour to non-tumour ratios after
administration of radiolabelled F(ab')2 fragments compared
with IgG. Other investigators demonstrated improved im-
munoscintigraphic detection of experimental tumours using
radiolabelled fragments (Buchegger et al., 1983; Hansson et
al., 1988; Gerretsen et al., 1991). Thus far, clinical data from
radioimmunodetection of cancer confirmed an increase in
sensitivity for F(ab')2 fragments compared with intact IgG
(Lamki et al., 1990).
For effective radioimmunotherapy, high radiation doses
absorbed in tumour tissue would be necessary. In the
OVCAR-3 model, we found iodinated MAbs as IgG to
deliver four to six times more radiation to tumours than the
F(ab')2 fragnents. Earlier, we have demonstrated that high
doses of '31I-labelled MAb 139H2 as IgG can induce com-
plete tumour regressions of particular human ovarian cancer
xenografts (Molthoff et al., 1992). Buchegger et al. (1990)
have suggested that repeated injections of high doses of
'3II-labelled anti-CEA F(ab')2 result in superior therapeutic
effects compared with equitoxic doses of 13"I-labelled IgG. In
this respect, F(ab')2 fragments may have an advantage be-
cause of the higher tumour to normal tissue ratios and the
lower bone marrow toxicity from faster blood clearance.
Moreover, smaller fragments of MAbs like F(ab')2 or Fab'
show a reduced immunogenicity compared with IgG. We
consider the lower absolute uptake in tumour tissue and the
short retention time as disadvantages for the use of F(ab')2
fragnents for treatment. Future studies should focus on the
precise role of IgG versus F(ab')2 in radioimmunotherapy.
From the three antibodies studied, MAb OV-TL 3 shows
the most favourable tumour uptake, but the cross-reactivity
with certain white blood cells may hamper its therapeutic
use. Of interest, the investigational MAb 139H2 has binding
characteristics which appear slightly better than MAb OC-
125. MAb 139H2 is known to have a broad reactivity pattern
with ovarian adenocarcinomas. Therefore, MAb 139H2
should be evaluated for its usefulness in the diagnosis of
ovarian cancer patients.
This work was supported by the Dutch Cancer Society. We thank
Dr H.J. Haisma for critically reading the manuscript.
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